What is the primary treatment for Candida albicans in cases of systemic infection?

The primary treatment for systemic infections caused by Candida albicans typically involves the use of Amphotericin B. This antifungal agent is recognized for its broad spectrum of action against various fungal pathogens, including those that cause severe systemic infections. Amphotericin B acts by binding to ergosterol in the fungal cell membrane, leading to membrane disruption and cell death. Its use is particularly critical in immunocompromised patients or those with severe infections where quick and effective intervention is necessary.

While other antifungals such as fluconazole and voriconazole have their uses, they are often employed in less severe cases of candidiasis or in patients who are more stable. Fluconazole, though effective against Candida albicans, is primarily utilized in cases that are less critical or for maintenance therapy after initial treatment. Voriconazole is mainly indicated for certain types of mold infections and does not have the same level of efficacy against Candida as Amphotericin B.

Nystatin is effective for topical and mucosal Candida infections, such as oral thrush, but it is not suitable for systemic infections due to its poor absorption from the gastrointestinal tract and is therefore not a first-line treatment for systemic Candida infections.